Editorial

The impact of statins on heart health: Beyond cholesterol lowering

Sayali Botwe

Department of Pharmacy, Government College of Pharmacy, Aurangabad, Maharashtra, India

Correspondence:
Sayali Botwe, Department of Pharmacy, Government College of Pharmacy, Aurangabad, Maharashtra, India.
E-mail: bsayali020@gmail.com

How to cite this article: Botwe S. The impact of statins on heart health: Beyond cholesterol lowering. Innov Pharm Planet 2023;11(1):11-13.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 25-01-2023
Date of Revision: 15-02-2023
Date of Acceptance: 22-02-2023

Statins and Cholesterol Lowering: The Traditional Role

Statins have become a cornerstone in cardiovascular care, primarily for their ability to lower low-density lipoprotein (LDL) cholesterol levels, which is essential in reducing the risk of atherosclerosis and coronary artery disease. They achieve this by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, a critical component in the cholesterol biosynthesis pathway in the liver. By blocking this enzyme, statins reduce cholesterol production, leading to a significant decrease in LDL levels within the bloodstream.[1]

The reduction in LDL cholesterol achieved with statin therapy is crucial, as elevated LDL is directly associated with plaque buildup in the arteries, which can lead to restricted blood flow and increased risk of heart attacks and strokes. Statins also promote the reabsorption of cholesterol from existing plaques, further preventing arterial narrowing. This dual impact – lowering circulating LDL cholesterol and stabilizing existing plaque – makes statins an invaluable tool in managing heart disease risk and has cemented their role in preventive cardiology for patients with high cholesterol and related cardiovascular risks.[2]

Anti-Inflammatory and Vascular Benefits

Beyond lowering LDL cholesterol, statins offer notable anti-inflammatory benefits, which contribute significantly to cardiovascular health. Chronic inflammation is a key factor in the progression of atherosclerosis, as it promotes plaque buildup and arterial damage. Statins help mitigate this risk by reducing levels of C-reactive protein (CRP), an inflammatory marker that, when elevated, is associated with a higher risk of cardiovascular events. By lowering CRP, statins reduce systemic inflammation, which can enhance cardiovascular outcomes independent of cholesterol levels.[3]

Statins also benefit vascular health by improving endothelial function – the health and responsiveness of the blood vessel lining. In individuals with endothelial dysfunction, a precursor to atherosclerosis, the endothelium produces less nitric oxide, a molecule vital for blood vessel relaxation and proper circulation. Statins increase nitric oxide availability, leading to better vasodilation, enhanced blood flow, and reduced risk of clot formation. This effect is particularly advantageous for patients with conditions that involve chronic inflammation, such as diabetes and rheumatoid arthritis, who face an elevated risk of vascular complications.[4]

Overall, the anti-inflammatory and vascular benefits of statins underscore their value in reducing cardiovascular risk, extending their impact beyond cholesterol management alone.

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275
DOI: 10.31690/ipplanet.2023.v011i01.003	

Oxidative Stress Reduction and Cellular Protection

Statins contribute to cardiovascular health not only by lowering cholesterol but also by acting as antioxidants, helping to counteract oxidative stress – a harmful process implicated in the development and progression of cardiovascular disease (CVD). Oxidative stress arises when there is an imbalance between free radicals, highly reactive molecules that can damage cells, and the body's antioxidant defenses. This imbalance can lead to cellular injury and inflammation, both of which are central to the formation of atherosclerotic plaques in blood vessels. By reducing oxidative stress, statins help to protect the cells lining the blood vessels, reducing the risk of plaque buildup and, in turn, heart disease.[5]

One of the primary ways statins achieve this is by inhibiting the production of reactive oxygen species (ROS) within cells. ROS are a type of free radical generated through metabolic processes, and in high levels, they can damage lipids, proteins, and DNA within the blood vessel walls. Statins help to curb this production, preventing ROS from attacking these critical cellular components and thereby maintaining vascular integrity. This antioxidant action helps limit the inflammatory response typically triggered by oxidative damage, creating a protective effect that complements the cholesterol-lowering benefits of statins.

In addition to directly limiting ROS production, statins also boost the activity of endogenous antioxidant enzymes, enhancing the body's natural ability to neutralize free radicals. For example, statins have been shown to increase the activity of superoxide dismutase and glutathione peroxidase, two enzymes that play crucial roles in scavenging free radicals and protecting cells from oxidative damage.[6] This ability to bolster the body's own defenses makes statins especially beneficial in patients with cardiovascular conditions, where oxidative stress is often elevated due to lifestyle factors such as smoking, obesity, and high blood pressure.

The combined effects of statins on oxidative stress reduction and cellular protection have far-reaching implications for CVD management. By shielding blood vessels from oxidative injury and supporting healthy cellular function, statins help reduce the risk of complications such as plaque rupture, blood clot formation, and heart attacks. These benefits position statins as a multifaceted therapeutic option for preventing and managing CVD, particularly in patients at high risk due to oxidative stress or inflammation.[7] Thus, statins' antioxidant properties play a vital role in reducing cardiovascular risk and supporting overall vascular health, adding a crucial layer of protection that goes beyond traditional cholesterol management.

Broadening the Use of Statins: Opportunities and Challenges

The traditional role of statins has centered around reducing LDL cholesterol levels in individuals at high risk of CVD. However, as our understanding of statins' diverse benefits grows, there is increasing interest in expanding statin therapy to patients who might not meet the conventional LDL threshold criteria but who present other risk factors for CVD. These may include elevated levels of inflammation, family history of heart disease, or the presence of comorbid conditions like diabetes or hypertension, which heighten cardiovascular risk regardless of cholesterol levels. Broadening the criteria for statin use represents an exciting opportunity to prevent CVD in a wider population, though it also raises important questions around appropriate patient selection, potential overuse, and personalized risk assessment.[8]

For patients who have additional risk factors beyond elevated LDL cholesterol, statins offer benefits that extend far beyond lipid control. For instance, individuals with high levels of CRP, an inflammatory marker associated with atherosclerosis progression, may benefit from the anti-inflammatory effects of statins even if their LDL levels are within a healthy range. Studies, such as the JUPITER trial, have demonstrated that statin therapy in patients with high CRP but normal LDL can significantly reduce the incidence of cardiovascular events, suggesting that these drugs can offer protection in those who would not traditionally qualify for statin therapy. Similarly, for patients with a family history of early-onset CVD or genetic predispositions, statins may provide a valuable preventive measure that takes into account inherited risk factors, helping to mitigate the influence of genetics on CVD outcomes.

The potential expansion of statin use, however, brings with it concerns regarding overprescription and the risk of adverse effects. While statins are generally well-tolerated, they can cause side effects such as muscle pain, liver enzyme elevation, and, in rare cases, more serious conditions like rhabdomyolysis. Moreover, some evidence suggests a slight increase in the risk of diabetes with long-term statin use, particularly in patients who are already predisposed to diabetes. Therefore, broadening the use of statins requires careful consideration to avoid exposing patients to unnecessary risks. This concern is especially relevant in individuals who might experience only marginal benefits, making the risk-benefit profile less favorable. As such, personalized assessment is critical to ensure that statin therapy is both safe and effective for each individual.[9]

Personalized risk assessment in the context of expanded statin therapy means looking beyond cholesterol levels alone and considering a range of factors, such as age, lifestyle, coexisting conditions, and family history. Tools such as the atherosclerotic CVD risk calculator, which estimates 10-year cardiovascular risk based on multiple parameters, can guide clinicians in determining which patients may benefit from statins despite having normal LDL levels. By integrating factors such as CRP levels, patient lifestyle, and genetic predispositions, health-care providers can make more nuanced decisions about statin therapy, optimizing its use for prevention while minimizing unnecessary risks.[10] In cases where statin therapy may not be suitable, clinicians can also consider alternative preventive measures, such as lifestyle modifications or other medications with fewer side effects.

Expanding the use of statins to patients with additional risk factors for CVD represents an important step toward a more comprehensive approach to cardiovascular prevention. However, this shift requires a

balanced perspective: while statins offer benefits beyond cholesterol reduction, they are not a universal solution. Each patient's unique risk profile must be evaluated to ensure that statin therapy is warranted and that the potential benefits outweigh the risks. With the growing emphasis on personalized medicine, the thoughtful expansion of statin therapy can enhance cardiovascular care, helping to prevent heart disease in broader, more diverse populations while maintaining a strong commitment to patient safety and individualized treatment.

Statins represent a multifaceted tool in cardiovascular health, providing benefits that extend far beyond cholesterol lowering. With careful, personalized risk assessment, expanding statin therapy could allow more patients to benefit from its diverse effects, fostering better outcomes in cardiovascular prevention and treatment. This broadened approach to statin use underscores the growing importance of integrating tailored care into cardiovascular medicine.

References

1. Hadjiphilippou S, Ray KK. Cholesterol-lowering agents: Statins-for everyone? Circ Res 2019;124:354-63.
2. Toth PP, Banach M. Statins: Then and now. Methodist Debakey Cardiovasc J 2019;15:23.
3. Satny, M., Hubacek, J. A., & Vrablik, M. (2021). Statins and inflammation. Current atherosclerosis reports, 23, 1-8.
4. Koushki K, Shahbaz SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Taba MY, *et al*. Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol 2021;60:175-99.
5. Liu A, Wu Q, Guo J, Ares I, Rodríguez JL, Martínez-Larrañaga MR, *et al*. Statins: Adverse reactions, oxidative stress and metabolic interactions. Pharmacol Ther 2019;195:54-84.
6. Sørensen AL, Hasselbalch HC, Nielsen CH, Poulsen HE, Ellervik C. Statin treatment, oxidative stress and inflammation in a Danish population. Redox Biol 2019;21:101088.
7. Mansouri A, Reiner Ž, Ruscica M, Tedeschi-Reiner E, Radbakhsh S, Bagheri Ekta M, *et al*. Antioxidant effects of statins by modulating Nrf2 and Nrf2/HO-1 signaling in different diseases. J Clin Med 2022;11:1313.
8. Byrne P, O'Donovan Ó, Smith SM, Cullinan J. Medicalisation, risk and the use of statins for primary prevention of cardiovascular disease: A scoping review of the literature. Health Risk Soc 2019;21:390-406.
9. He M, Lv W, Rao Y. Opportunities and challenges of small molecule induced targeted protein degradation. Front Cell Dev Biol 2021;9:685106.
10. Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: Therapeutic opportunities and challenges. Nat Rev Drug Discov 2022;21:283-305.